Article Text

Download PDFPDF
Trial of ganglioside GM1 in acute stroke.
  1. B I Hoffbrand,
  2. P J Bingley,
  3. S M Oppenheimer,
  4. C D Sheldon
  1. Department of Medicine, Whittington Hospital, London, UK.


    Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • Research Article
      I Appollonio L Frattola M Massarotti